London medical school specialising in infectious disease vaccines, congenital anomaly surveillance, and plant-based pharmaceutical manufacturing across 42 countries.
St George's, University of London (SGUL) is a specialist health sciences university and teaching hospital in London focused on infectious disease, maternal and child health, and vaccine development. They run major European registries tracking congenital anomalies in children (EUROlinkCAT) and lead clinical drug development for neglected tropical diseases like leishmaniasis. Their applied research spans from tuberculosis mucosal immunity and antimicrobial-resistant bacteria vaccines to plant molecular farming for pharmaceutical production. As a clinical-academic institution, they bridge laboratory research with hospital-based patient data and public health surveillance.
Coordinated EUROlinkCAT (EUR 2M) building a linked European cohort of children with congenital anomalies, contributed to ZikaPLAN on Zika-related birth defects, and Equal-Life on early-life health effects.
Coordinated EMI-TB (EUR 2.2M) on tuberculosis mucosal immunity, participated in BactiVax training network on antimicrobial-resistant bacteria vaccines, and NeoIPC on infection prevention in neonatal intensive care.
Coordinated Pharma-Factory (EUR 1.6M) on plant-based pharmaceutical production and participated in Newcotiana (CRISPR-based Nicotiana crops) and PhotoBoost on crop photosynthetic performance.
Coordinated TT4CL (EUR 1.2M) for clinical development of oleylphosphocholine as a treatment for cutaneous leishmaniasis through Phase I trials.
Participated in iPLACENTA on placental modelling for pre-eclampsia and ConcePTION on medication safety monitoring during pregnancy and lactation.
Participated in AsthmaPhenotypes (ERC-funded) on asthma beyond atopic/non-atopic classification and CAMERA on non-atopic asthma mechanisms in children.
In the early period (2015–2018), SGUL focused on infectious disease response (Zika preparedness, TB vaccines), congenital anomaly registries, and public health interventions like smoking prevention and cardiovascular diagnostics. From 2019 onward, the focus shifted markedly toward pregnancy pharmacovigilance, neonatal infection control, childhood asthma mechanisms, and environmental exposome effects on mental health — reflecting a deepening commitment to maternal-child health across the full lifecycle. The plant molecular farming thread also matured, moving from basic platform development to CRISPR-enabled crop engineering.
SGUL is consolidating around a maternal-child health pipeline — from pregnancy safety through neonatal care to childhood disease — making them a strong partner for projects spanning perinatal and paediatric research.
SGUL operates primarily as an active partner (13 of 17 projects) but takes the coordinator role for their strongest specialisms — congenital anomalies, TB vaccines, plant pharma, and drug development. With 249 unique consortium partners across 42 countries, they are a well-connected hub rather than a repeat-partner institution. Their coordinator projects tend to be large (EUR 1.2–2.2M funding to SGUL), indicating they lead when they have deep domain ownership and join as specialist contributors in broader consortia.
Extensive European network spanning 249 unique partners across 42 countries, indicating reach well beyond the UK into Latin America (ZikaPLAN) and global health networks. Their partnerships cover clinical centres, registries, plant science labs, and public health agencies — a unusually diverse partner base for a medical school.
SGUL combines clinical hospital infrastructure with research strengths in an unusual pairing: infectious disease vaccines AND plant molecular farming for pharmaceutical production. Few medical schools in Europe can offer both patient-facing clinical trial capability and biomanufacturing expertise using plant-based systems. Their EUROlinkCAT coordinator role also gives them privileged access to one of Europe's largest linked datasets on children with congenital anomalies — a unique asset for any consortium working on birth defects, paediatric outcomes, or health data linkage.
